Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON46104
NL-OMON46104
Recruiting
Not Applicable

Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer - Circle study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites79 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
79
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- metastasized prostate cancer
  • •\- age \* 18 years
  • •\- Written informed consent of the patient
  • •\- \* 2 adequate peripheral veins as access point for leukapheresis

Exclusion Criteria

  • •\- CTC count of \< 5 CTCs/7\.5 mL of blood
  • •\- Patients with a known hypersensitivity to the used LA\-anticoagulant
  • •\- mHSPC patients with current ADT
  • •\- Hemorrhage disease and/or coagulation disorder
  • •\- Inadequate liver and/or renal function
  • •\- Inadequate hematology and coagulation status
  • •\- Chronic viral infections

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Generation of circulating tumor cell derived organoidsthrough enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancerProstate cancerCRPCHSPCMetastatic prostate cancer
NL-OMON29626Eramus Medical Center Rotterdam46
Completed
Not Applicable
Relevance of circulating tumour cells in patients undergoing laparoscopic colon resection versus open resection: a randomised trialColorectal cancerCancerMalignant neoplasm of the colorectal area
ISRCTN28212149Academic Medical Centre (AMC) (Netherlands)30
Completed
Not Applicable
Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetectorProstate cancer (all stages), Benign prostatic hyperplasia (all stages)CancerMalignant neoplasm of prostate
ISRCTN10403616GILUPI GmbH (Germany)105
Recruiting
Not Applicable
Clinical relevance of circulating tumor cells, ctDNA and diagnostic leukapheresis in pancreatic ductal adenocarcinoma patientsC25Malignant neoplasm of pancreas
DRKS00023362niversitätsklinikum Hamburg-Eppendorf50
Completed
Not Applicable
In vivo isolation of circulating tumor cells from peripheral blood of patients with lung cancer by using a structured antibody-coated nanodetectorung cancer (non small cell lung cancer - NSCLC, stage I-IV)CancerMalignanat neoplasm of bronchus or lung, unspecified
ISRCTN55277999GILUPI GmbH (Germany)60